Screener
Denali Therapeutics Inc. DNLI Business Segments — Operating Expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Denali Therapeutics Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostsAndExpenses.
The source filing: Denali Therapeutics Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:08 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001714899-26-000097
| Line item | Therapeutics Segment / Three Months Ended June 30, 2026 | Therapeutics Segment / Three Months Ended June 30, 2025 | Therapeutics Segment / Six Months Ended June 30, 2026 | Therapeutics Segment / Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Personnel related selling, general and administrative expenses | 22,921 | 20,115 | 45,485 | 38,853 |
| Other selling, general and administrative expenses | 13,362 | 12,152 | 24,309 | 22,767 |
| Total selling, general and administrative expenses | 36,283 | 32,267 | 69,794 | 61,620 |
| Intangible asset amortization | $750 | — | $750 | — |
| Segment operating expenses | 134,145 | 134,963 | 271,502 | 280,543 |
| Segment loss from operations | (130,541) | (134,963) | (267,898) | (280,543) |
| Segment interest and other income, net | 2,988 | 10,844 | 11,898 | 23,454 |
| Segment net loss | $(127,553) | $(124,119) | $(256,000) | $(257,089) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Denali Therapeutics Inc.'s business segments — operating expenses?
- Denali Therapeutics Inc. (DNLI) reported business segments — operating expenses of $134.15M in Q2 2026.
- How has Denali Therapeutics Inc.'s business segments — operating expenses changed year-over-year?
- Denali Therapeutics Inc.'s business segments — operating expenses decreased by 0.6% year-over-year, from $134.96M to $134.15M.
- What is the long-term trend for Denali Therapeutics Inc.'s business segments — operating expenses?
- Over 3 years (2022 to 2025), Denali Therapeutics Inc.'s business segments — operating expenses has grown at a 7.3% compound annual growth rate (CAGR), from $449.21M to $555.34M.
- What does business segments — operating expenses mean?
- The sum of all research, development, and administrative costs incurred during the period. This metric represents the total cash outflow required to sustain the company's operations before accounting for revenue or financing activities. It is a critical measure for evaluating the company's overall operational scale and cash burn.
Ask your AI about Denali Therapeutics Inc.'s business segments — operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude